Strategies To Ease Short-Term Earnings Pain From Health Reform Include Cost-Cutting, Diversification
Executive Summary
With market-based fees and increased Medicaid rebates set to start several years before drug manufacturers will see any benefit of an expanded market from health care reform, consultants are suggesting several ways to counter the short-term negative effect on earnings, including continued cost-cutting and diversification
You may also be interested in...
$8 Billion And Counting: Pharma Paying Its ACA Taxes
HHS OIG report shows pharma industry fee is being paid, albeit with a few bumps along the way.
$8 Billion And Counting: Pharma Paying Its ACA Taxes
HHS OIG report shows pharma industry fee is being paid, albeit with a few bumps along the way.
Amgen Highlights Effects Of Health Reform Provisions In Earnings Call
While Amgen's bottom line will take a hit in the wake of the new health care reform law, the impact is expected to minimal enough that officials did not have to change previously reported guidance